anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain a percutaneous integrated system high in permeation of a medicine through the skin without causing irritating effect by adding a combination of eucalyptol and an additional fluidity enhancer to an adhesive layer composed of a permeable polymer material containing a medicine. CONSTITUTION: This percutaneous treating system comprises (A) a backing layer impermeable to components of an adhesive layer, (B) an adhesive layer composed of a combination of a permeable polymer material which can release a medicine, is compatible with the skin and contains a medicine (e.g. nitroglycerine or scopolamine) permeable through the skin, eucalyptol having >=70% purity (a mixture comprising >=95% 1,8-cineole and an additional fluidity enhancer and optionally a medicine excipient and (C) a protective releasable liner. N- Methyl-2-pyrrolidone is preferable as the additional fluidity enhancer. Preferably, 5-9.5 pts.wt., especially 9 pts.wt. of chemically pure 1,8-cineole is combined with 5-0.5 pt.wt., especially 1 pt.wt. of N-methyl-2-pyrrolidone.
The hepatitis C virus (HCV) is one of the most common bloodborne pathogens in the United States. A large proportion of people with HCV infection progress to chronic HCV infection despite the availability of effective treatment; chronic infection can result in cirrhosis, end-stage liver disease, liver cancer, and liver-related death. HCV infection can be cured most of the time with treatment. The objective of this before and after study is to evaluate whether sending alerts to healthcare providers and clinic staff to identify patients with untreated hepatitis C infection can increase the uptake of HCV treatment. A period of time without alerts will be compared to a period of time with alerts. Healthcare providers and clinic staff will not receive alerts during the before period of the study. Healthcare providers and clinic staff will receive alerts during the after period of the study.
The invention discloses a long-acting sustained controlled release formulation of donepezil-like composition and a process for preparation. The composition is in the shape of micro-granular. According to the measurement by weight, the invention contains donepezil-like compounds 0.5-5 parts, carrier material of the sustained controlled release formulation 1-500 parts, and further contains other common excipient in pharmacy. The composition is used for anti senile dementia. The frequency of donepezil-like compounds is reduced, and the periodic time of administering medicament is prolonged, the compliance and conformability of the patient are improved, and the bioavailability and the therapeutic index of the donepezil are promoted. Meanwhile the invention discloses a plurality of processes for the preparation of long-acting sustained controlled release formulation of donepezil-like compounds. The process for preparation is flexible. Common processing equipment and commercial scale can be adopted. The production efficiency is high and the quality keeps steady. The invention can be directly or secondly used for making injection or medicament for oral administration.
Carbidopa, USP is an inhibitor of aromatic amino acid decarboxylation. It is white to creamy white powder, freely soluble in 3N hydrochloric acid, slightly soluble in water and methanol, practically insoluble in alcohol, in acetone, in chloroform and in ether, with a molecular weight of 244.24. It is designated chemically as (–)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its molecular formula is C10H14N2O4•H2O and its structural formula is:

Carbidopa tablets contain 25 mg of carbidopa, USP. Inactive ingredients are crospovidone type B, ferric oxide red, ferric oxide yellow, hydroxypropyl cellulose, magnesium stearate, mannitol and microcrystalline cellulose.

Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.3.
Vardenafil was evaluated in four major double-blind, randomized, placebo-controlled, fixed-dose, parallel design, multicenter trials in 2431 men aged 20-83 (mean age 57 years; 78% White, 7% Black, 2% Asian, 3% Hispanic and 10% Other/Unknown). The doses of vardenafil hydrochloride tablets in these studies were 5 mg, 10 mg, and 20 mg. Two of these trials were conducted in the general erectile dysfunction (ED) population and two in special ED populations (one in patients with diabetes mellitus and one in post-prostatectomy patients). Vardenafil hydrochloride tablet was dosed without regard to meals on an as needed basis in men with ED, many of whom had multiple other medical conditions. The primary endpoints were assessed at 3 months.   
Primary efficacy assessment in all four major trials was by means of the Erectile Function (EF) Domain score of the validated International Index of Erectile Function (IIEF) Questionnaire and two questions from the Sexual Encounter Profile (SEP) dealing with the ability to achieve vaginal penetration (SEP2), and the ability to maintain an erection long enough for successful intercourse (SEP3).   
In all four fixed-dose efficacy trials, vardenafil hydrochloride tablets showed clinically meaningful and statistically significant improvement in the EF Domain, SEP2, and SEP3 scores compared to placebo. The mean baseline EF Domain score in these trials was 11.8 (scores range from 0-30 where lower scores represent more severe disease). Vardenafil hydrochloride tablets (5 mg, 10 mg, and 20 mg) were effective in all age categories (<45, 45 to <65, and ≥65 years) and were also effective regardless of race (White, Black, Other).
FIELD: veterinary pharmacology, chemotherapy. SUBSTANCE: the suggested preparation contains levomycetin succinate, tetracycline, sulfanylamide preparation as sulfaethadol, novocaine, ascorbic acid, 1,2-propylene glycol and twin-80 at certain quantitative ratio of components. Preparation of high efficiency (about 95-98%) is tested in some failed farm upon groups of calves, pigs and lambs. The innovation could be applied at large-scale cattle-breeding complexes and in private sector in case of respiratory and gastro-intestinal diseases in farm animals. EFFECT: higher efficiency of therapy. 6 tbl
Examples herein include methods, systems, and computer program products for utilizing neural networks in ultrasound systems. The methods include processor(s) of a computing device identifying a neural network for implementation on the computing device to generate, based on ultrasound data, inferences and confidence levels for the inferences, the computing device being communicatively coupled via a computing network to an ultrasound machine configured to generate the ultrasound data. The processor(s) implements the neural network on the computing device, including configuring the neural network to generate an inference and a confidence level for at least one image of the images. The processor(s) obtains the ultrasound data including images from the ultrasound machine. The processor(s) determines, for the at least one image, an accuracy of the inference and the confidence level. The processor(s) automatically reconfigures the neural network to increase the accuracy based on the determining the accuracy.
The patient receives acupuncture session lasts between 20 to 30 minutes. Acupuncture will be applied according to the standards for reporting interventions in clinical trials of acupuncture (STRICTA).
Metastasis is the leading cause of cancer-related deaths. Despite this relevance, there is no specific therapy targeting metastasis. The interaction of the tumor cell with platelets, forming microemboli is crucial for successful hematogenous dissemination. Heparin disrupts it by a P-selectin-mediated event. However, its clinical use for this purpose is hindered by the requirement of high doses, leading to anticoagulant-related side effects. In this study, we obtained a low-anticoagulant heparin through the fractionation of a pharmaceutical bovine heparin. This derivative was referred to as LA-hep and we investigated its efficacy in inhibiting metastases and explored its capacity of suppressing the interaction between tumor cells and platelets. Our data revealed that LA-hep is as efficient as porcine unfractionated heparin in attenuating lung metastases from melanoma and colon adenocarcinoma cells in an assay with a single intravenous administration. It also prevents platelet arrest shortly after cell injection in wild-type mice and suppresses melanoma-platelets interaction in vitro. Moreover, LA-hep blocks P-selectin's direct binding to tumor cells and platelet aggregation, providing further evidence for the role of P-selectin as a molecular target. Even in P-selectin-depleted mice which developed a reduced number of metastatic foci, both porcine heparin and LA-hep further inhibited metastasis burden. This suggests evidence of an additional mechanism of antimetastatic action. Therefore, our results indicate a dissociation between the heparin anticoagulant and antimetastatic effects. Considering the simple and highly reproducible methodology used to purify LA-hep along with the data presented here, LA-hep emerges as a promising drug for future use in preventing metastasis in cancer patients.
Breast cancer patients no treated by adjuvant chemotherapy after their surgery. For patients treated by radiotherapy after surgery, there are 2 measurement points pre- and post radiotherapy. The others measurement points are at 4,6,7,8,12,18 and 24 months after surgery.
Objective is to characterize the relationship between genetic polymorphisms and inter-individual variability in plasma statin and metabolite concentration(s) and to quantify its contribution towards clinically significant statin induced muscle ADR phenotypes myopathy and/or myalgia in Singapore population. Methodology: This research involves the study of two different kinds of muscle ADRs commonly associated with statin therapy, namely myalgia and myopathy. The study of myalgia will include the recruitment and sample collection (blood)from 3000 subjects from the outpatient clinic at NUH and NHC, who are on either simvastatin or atorvastatin. To identify genetic variants associated with altered stain exposure, investigators will perform an analysis of the drug and metabolite levels in plasma, followed by a genetic analysis of DNA from the blood samples of the recruited subjects. A subgroup of 30 subjects (15 from NUH and 15 from NHC) from this large cohort will be used to study intra-subject variability in statin drug and metabolite exposure. The genetic association analysis of genotype and statin blood measurements will be done using liner regression analysis. To test the hypothesis that related pharmacokinetic variants are associated with myalgia and myopathy, investigators will perform the case-control association analysis using logistic regression to examine the frequency of genetic variant in patients with clinically identified ADRs and compare it to control subjects without any ADRs. A separate cohort of 200 subjects will be recruited for the myopathy study through the NUH outpatient clinic following subject identification through an IRB approved medical records review of patients who were/are any statin drug/dose. Blood samples collected from these patients will be subjected to genetic analysis to identify genetic variants associated with symptomatic phenotypes.

Potential Benefits and risks: The potential benefits of this study include, identifying strong risk factors of statin induced muscle symptoms myalgia/myopathy that should inform clinical practice in minimizing/ managing severity of statin associated muscle symptoms, by identifying patient populations with an increased risk to statin induced myalgia and/or myopathy. This information might ultimately inform treatment decisions including drug selection and dosing and improved prediction of treatment response in a heterogeneous population. The only possible risk in the study is that associated with blood-taking. Obtaining blood can cause pain, bleeding, bruising, or swelling at the site of the needle stick. Fainting sometimes occurs and infection rarely occurs.
PROBLEM TO BE SOLVED: To provide a method and a product for identifying a modulator of P2X7 receptor activities, and to provide their use in the treatment of skeleton disorder. SOLUTION: This method comprises identifying therapeutic candidates for modulating bone mass and/or bone mineral density by screening compounds. A method for treating the skeletal disorder the decreased bone mass and/or bone mineral density to provided. The method is based upon the identification and use of agonists of the P2X7 receptor. The method for identifying the therapeutic candidate for increasing the bone mass and/or the bone mineral density by screening a compound comprises detecting the index of the P2X7 receptor activities by bringing the test compound into contact with the P2X7 receptor under the conditions which, in the presence of the compound, permits the binding of the P2X7 receptor to a P2X7 receptor ligand. The increase of the index indicates that the compound is the candidate for increasing the bone mass and/or the bone mineral density by interacting with the P2X7 in vivo.
Antigenicity of peptides, polypeptides, proteids and proteins is evoked, increased or altered by the use of xenogenic nucleic acids (DNA or RNA). Pref. nucleic acids are from calf foetuses, although nucleic acid from other sources can be used. The xenogenic nucleic acids (which are themselves non-toxic and non-antigenic) increase antigenicity so that smaller amounts of antigenic (poly) peptide, proteid or protein are required to bring about the formation of antigen (e.g. in active or passive immunisation against injurious substances or tissues (e.g. cancer tissues) or pathogenic organisms or microorganisms such as viruses or bacteria).
Glucose monitoring is essential for patients receiving insulin therapy. Changes to an insulin regimen should be made cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose. Concomitant oral antidiabetic treatment may need to be adjusted. 

As with all insulin preparations, the time course of action for HUMALOG may vary in different individuals or at different times in the same individual and is dependent on many conditions, including the site of injection, local blood supply, or local temperature. Patients who change their level of physical activity or meal plan may require adjustment of insulin dosages.
The participants were randomly assigned to receive medicated with SRP combined with intrasulcular application of placebo gel. After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort. Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing).
PURPOSE: R12-Grim19 fusion peptide is provided to be usefully used as an immune suppressant or a pharmaceutical composition which prevents or treats immune disease including autoimmune disease due to the modulation of an immune reaction, inflammation disease and transplantation rejection disease. CONSTITUTION: Recombinant peptide in which twelve successive arginene (R) and Grim19 are fused is provided. The recombinant peptide has an amino acid sequence represented by a sequence number 1. A vector includes a base sequence coding the peptide. The base sequence comprises a base sequence represented by a sequence number 2. A composition for prevention or treatment of the immune disease includes the peptide.
Patients presenting for surgical management of a chronic total knee arthroplasty (TKA) prosthetic joint infection (PJI). Patients will be excluded if they are less than 18 years of age, have a prior history of ipsilateral or contralateral PJI warranting operative management, or are unable to provide informed consent.
This study is a randomized, double blind, parallel group, placebo controlled study, in which subjects, with no evidence of prior C.jejuni infections or immunity, will be vaccinated with ACE393, a protein sub-unit vaccine, or placebo, and then subsequently challenged with C.jejuni. The study will include vaccination of approximately 72 subjects, with the aim of challenging a total of 60 subjects. ACE393 or placebo will be administered twice by intramuscular injection on an outpatient basis, three weeks apart and then the subjects will be challenged three weeks later with C.jejuni. During the inpatient monitoring period, volunteers will be evaluated daily for safety, clinical signs and symptoms of disease and stool microbiology). Criteria for early institution of oral hydration, intravenous fluids, serum electrolyte monitoring, blood cultures, and/or antibiotics are predefined. All volunteers will receive antibiotic therapy 6 days after challenge (unless treated early). Discharge criteria are predefined. Post-discharge follow-up will further monitor safety, confirm C .jejuni eradication after antibiotic therapy, and assess immunologic response.
Participants were daily self-administered with fumaric acid derivatives initial and maintenance therapy in dosetitrated scheme as per protocol. Dose was up-titrated weekly (1 tablet/day) until objective was achieved or until tapering was required or until the maximum dose of 2 tablets each at morning, noon and evening was reached, whichever occurred earlier.
A digital photo frame with a mirror function is provided. The digital photo frame includes a power source, a power management unit, a display panel, a backlight module, an image capture unit and a processing unit. The display panel includes a mirror film. The power management unit is used to manage the power supply from the power source to each component of the digital photo frame. The backlight module connects with the display panel and the power management unit. The image capture unit is used to produce an off signal when detects someone near the digital photo frame. The processing unit connects with the touch sense unit and the power management unit, when the processing unit receives the off signal produced by the touch sense unit, the processing unit controls the management unit to stop the power supply from the power source to the backlight module.
The present invention relates to the field of medicine and in particular to celiac disease (CD). Specifically the present invention relates to methods and means for detection of CD using novel microbiomarker, celiac gut index (CGI). The invention relates also to methods and means for treatment or prophylaxis of CD. The present invention provides a novel product comprising a gut microbiome altering agent that, when administered to an individual, improves the state of health of individuals suffering or susceptible to suffer from celiac disease and possibly reduces the likelihood of acquiring celiac disease. The product of the invention provides a natural and safe manner for the treatment of celiac disease. The present invention provides also a novel method for aiding diagnosis of CD by the specific gut health biomarker, Celiac Gut Index (GCI). In the method a probability of a subject having celiac disease is determined by measuring the relative abundances of one or more microbial taxa in a fecal sample from a subject; and the probability of the subject having CD is determined based on the measured abundances as celiac gut index (CGI).
Early indicators of metastatic cancer response to therapy are important for evaluating new drugs and stopping ineffective treatment. The RECIST guidelines based on repeat cancer imaging are widely adopted in clinical trials, are used to identify active regimens that may change practice, and contribute to regulatory approvals. However, these criteria do not provide insight before 6 to 12 weeks of treatment and typically require that patients have measurable disease. Recent data suggest that measuring on-treatment changes in the amount or proportion of ctDNA in peripheral blood plasma may accurately identify responding and nonresponding cancers at earlier time points. Over the past year, the RECIST working group has evaluated current evidence for plasma ctDNA kinetics as a treatment response biomarker in metastatic cancers and early endpoint in clinical trials to identify areas of focus for future research and validation. Here, we outline the requirement for large standardized trial datasets, greater scrutiny of optimal ctDNA collection time points and assay thresholds, and consideration of regulatory body guidelines and patient opinions. In particular, clinically meaningful changes in plasma ctDNA abundance are likely to differ by cancer type and therapy class and must be assessed before ctDNA can be considered a potential pan-cancer response evaluation biomarker. Despite the need for additional data, minimally invasive on-treatment ctDNA measurements hold promise to build upon existing response assessments such as RECIST and offer opportunities for developing novel early endpoints for modern clinical trials.
Mitochondrial dysfunction is recognized as a pivotal contributor to the pathogenesis of renal ischemia-reperfusion (IR) injury. Mitophagy, the process responsible for removing damaged protein aggregates, stands as a critical mechanism safeguarding cells against IR injury. Currently, the role of deubiquitination in regulating mitophagy still needs to be completely elucidated. This study aimed to evaluate the impact of ubiquitin-specific peptidase 14 (Usp14), a deubiquitinase, in IR injury by influencing mitophagy. Utilizing a murine model of renal IR injury, Usp14 silencing was found to ameliorate kidney injury, leading to decreased levels of serum creatinine and blood urea nitrogen, alongside diminished oxidative stress and inflammation. In renal epithelial cells subjected to hypoxia/reoxygenation (H/R), Usp14 knockdown increased cell viability and reduced apoptosis. Further mechanistic studies revealed that Usp14 interacted with and deubiquitinated transcription factor AP-2 alpha (Tfap2a), thereby suppressing its downstream target gene, TANK binding kinase 1 (Tbk1), to influence mitophagy. Tfap2a overexpression or Tbk1 inhibition reversed the protective effects of Usp14 silencing on renal tubular cell injury and its facilitation of mitophagy. In summary, our study demonstrated the renoprotective role of Usp14 knockdown in mitigating renal IR injury by promoting Tfap2a-mediated Tbk1 upregulation and mitophagy. These findings advocate for exploring Usp14 inhibition as a promising therapeutic avenue for mitigating IR injury, primarily by enhancing the clearance of damaged mitochondria through augmented mitophagy.
Teduglutide, 4 mg, SC injection using a syringe, once on Day 1 of Treatment Period 1 (Treatment A2), followed by same dose SC pen injector, once on Day 1 of Treatment Period 2 (Treatment B2). A Washout Period of 7 days was maintained between Treatment Periods 1 and 2. Participants \>75.0 kg to \<=120.0 kg of weight were included in Cohort 2.
Part A: Single dose (\~ 24 ) Healthy Volunteers: At least four consecutive ascending dose cohorts (20 mg, 40, 80 and 160 mg) will be included in this part of the study in accordance with a pre-defined dose escalating scheme. In each cohort, 6 HVs will receive a single dose of investigation medicine product (CMND-100) starting with the lowest dose of 20 mg. Once dosed, the subjects will be sampled for PK for 24 hours following dosing and will be monitored for drug effects with a physical examination at the end of 24 hours after dosing and daily monitored for safety for a period of 1 week following dosing. Assuming no serious adverse reactions or limiting toxicity (grade 2 and higher) in up to 2, subjects are observed in this dose level, then the next 6 subjects are treated with the next escalated dose, in accordance with a pre-defined dose escalating scheme. The DSMB will review results and guide doses to be studied in Parts B, C and D.